| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2877021 | The Annals of Thoracic Surgery | 2012 | 9 Pages |
Abstract
For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear. Induction therapy for cT2 N0 did not translate into a statistically significant improvement in survival. However, due to the significant understaging of T2 N0 patients, we recommend neoadjuvant therapy to all cT2N0 patients before operation.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jennifer Q. BS, Craig M. MPH, Malcolm V. MD, James BS, Sue BS, Remealle MD, Noreli PhD, Helen BS, Alicia MD, Stephen C. MD,